scholarly journals Comparison of SOX-10, HMB-45, and Melan-A in Benign Melanocytic Lesions

2021 ◽  
Vol Volume 14 ◽  
pp. 1419-1425
Author(s):  
Sabrina E Dass ◽  
Taryn Huizenga ◽  
Mehdi Farshchian ◽  
Darius R Mehregan
Keyword(s):  
2007 ◽  
Vol 131 (1) ◽  
pp. 122-125 ◽  
Author(s):  
Andres A. Roma ◽  
Cristina Magi-Galluzzi ◽  
Ming Zhou

Abstract Context.—Renal angiomyolipoma is a tumor composed of varying amounts of fat, smooth muscle, and blood vessels. Characteristically, tumor cells express melanocytic markers such as HMB-45 and Melan-A. Recently, several other markers have been described as having excellent diagnostic sensitivity in cutaneous melanocytic lesions. Objectives.—To compare the sensitivities of 5 melanocytic markers in renal angiomyolipoma and to study the expression patterns of these markers in the 3 different components of angiomyolipoma. Design.—A tissue microarray of 20 renal angiomyolipomas was constructed. For each case, 3 cores containing fat, blood vessels, and smooth muscle were taken. The tissue microarray was then stained for HMB-45, Melan-A, tyrosinase, NK1-C3, and CD117. Results.—HMB-45 was positive in 95%, Melan-A in 85%, NK1-C3 in 70%, tyrosinase in 50%, and CD117 in 40% of the cases. All (20/20) were positive for HMB-45 and Melan-A combined. These 5 markers had different sensitivities in the 3 components. HMB-45 was positive in 90%, 85%, and 80% of fat, smooth muscle, and blood vessel components, respectively; Melan-A in 70%, 60%, and 40%; NK1-C3 in 55%, 55%, and 45%; tyrosinase in 30%, 40%, and 10%; and CD117 in 20%, 40%, and 10%, respectively, of these 3 components. Conclusions.—HMB-45 and Melan-A combined were positive in 100% of the renal angiomyolipomas. We recommend the use of these 2 markers in the workup of this entity, including those with predominantly 1 component. Other melanocytic markers are of limited use. A tissue block comprising predominantly fat or smooth muscle components should be used when performing melanocytic marker immunostain.


2021 ◽  
Vol 8 (9) ◽  
Author(s):  
Darrell J Johnston ◽  
Phuoc-Tan Diep

Diagnostic pitfalls have been widely documented on atypical naevi, a group of pigmented lesions that occupy a grey portion between benign and malignant variants. As malignant melanoma is associated with a high mortality rate it is vital we have a reliable diagnostic testing method for these challenging lesions. A pilot study was proposed using dual immunohistochemistry staining with a new depth measurement, the Lancaster depth, to develop a validating tool to measure difficult atypical lesions against. The Lancaster depth was recorded for 68 pigmented lesions; 34 benign and 34 malignant, where measurement was taken from the granular layer to the deepest HMB-45/Ki67 dual stained melanocyte. This measurement was compared against the established Breslow depth measurement where the distance between the two was of interest. The mean malignant Lancaster depth at 1.51mm was higher than that of the benign at 0.12mm. There was a statistically significant difference of 1.40mm, P = <.001. There was a statistically significant difference between the mean Lancaster and Breslow depths in both malignant and benign lesions. In the malignant group this was 0.28mm, P = <.001 compared to the benign which was 1.07mm, P = <.001. A narrow distance ratio between the two depths indicated a malignant diagnosis. A wider distance ratio was indicative of a benign diagnosis. As a diagnostic validator the Lancaster depth shows promises but has limitations as a standalone model. Working in conjunction with the Breslow depth we potentially have a useful adjunct to accurately diagnose difficult atypical lesions.


Dermatology ◽  
1997 ◽  
Vol 194 (4) ◽  
pp. 344-350 ◽  
Author(s):  
D. Kopera ◽  
U. Hohenleutner ◽  
W. Stolz ◽  
M. Landthaler

1991 ◽  
Vol 13 (6) ◽  
pp. 543-550 ◽  
Author(s):  
Henry G. Skelton ◽  
Kathleen J. Smith ◽  
Terry L. Barrett ◽  
George P. Lupton ◽  
James H. Graham
Keyword(s):  

Ophthalmology ◽  
1991 ◽  
Vol 98 (4) ◽  
pp. 453-458 ◽  
Author(s):  
Jan M. McDonnell ◽  
Yan Yu Sun ◽  
David Wagner

Author(s):  
J.M. Minda ◽  
E. Dessy ◽  
G. G. Pietra

Pulmonary lymphangiomyomatosis (PLAM) is a rare disease occurring exclusively in women of reproductive age. It involves the lungs, lymph nodes and lymphatic ducts. In the lungs, it is characterized by the proliferation of smooth muscle cells around lymphatics in the bronchovascular bundles, lobular septa and pleura The nature of smooth muscle proliferation in PLAM is still unclear. Recently, reactivity of the smooth muscle cells for HMB-45, a melanoma-related antigen has been reported by immunohistochemistry. The purpose of this study was the ultrastructural localization of HMB-45 immunoreactivity in these cells using gold-labeled antibodies.Lung tissue from three cases of PLAM, referred to our Institution for lung transplantation, was embedded in either Poly/Bed 812 post-fixed in 1% osmium tetroxide, or in LR White, without osmication. For the immunogold technique, thin sections were placed on Nickel grids and incubated with affinity purified, monoclonal anti-melanoma antibody HMB-45 (1:1) (Enzo Diag. Co) overnight at 4°C. After extensive washing with PBS, grids were treated with Goat-anti-mouse-IgG-Gold (5nm) (1:10) (Amersham Life Sci) for 1 hour, at room temperature.


Sign in / Sign up

Export Citation Format

Share Document